Welcure Drugs & Pharmaceuticals Ltd
Welcure Drugs reports Q4 FY26 Net Loss of (Rs. 5,003.73) Lacs; supersedes prior filing
RESULTS
▼ Concern Flagged
HIGH RISK
📅 Filed on BSE: 02 Nov 2026, 05:45 PM IST · BSE ID: 8cdcc7fe-243d-444c-89e3-0bf7d6ab0ce8
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its financial results for the full year ending March 2026, showing a loss for both the quarter and the full year.
🤖 AI Summary
- Board approved Audited Standalone Financial Results for quarter and year ended March 31, 2026.
- Total Income for Q4 FY26 was (Rs. 0) Lacs; Net Loss for Q4 FY26 stood at (Rs. 5,003.73) Lacs.
- Full year FY26 reported Total Income of (Rs. 39,098.87) Lacs, with Net Loss of (Rs. 567.08) Lacs.
- This filing supersedes earlier results from May 29, 2026, correcting inadvertent errors.
- Basic and Diluted EPS for Q4 FY26 was (Rs. 0.40), and (Rs. 0.05) for the full year FY26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Income (Q4 FY26)
(Rs. 0) Lacs
Not comparable — limited prior period data.
Net Profit/(Loss) (Q4 FY26)
(Rs. 5,003.73) Lacs
Not comparable — limited prior period data.
Total Income (FY26)
(Rs. 39,098.87) Lacs
1370.47%
Net Profit/(Loss) (FY26)
(Rs. 567.08) Lacs
Not comparable — limited prior period data.
Basic EPS (Q4 FY26)
(Rs. 0.40)
Not comparable — limited prior period data.
Basic EPS (FY26)
(Rs. 0.05)
Not comparable — limited prior period data.
🏢 How This Affects the Company
The company's primary revenue stream for the quarter ended March 31, 2026, was zero from operations and nil from other income, indicating a halt in revenue-generating activities for that specific quarter.
Welcure Drugs & Pharmaceuticals Ltd. recorded a Net Loss of (Rs. 5,003.73) Lacs for Q4 FY26 and a full-year Net Loss of (Rs. 567.08) Lacs, significantly impacting overall profitability and shareholder equity, which shows a negative balance of (Rs. 2,674.47) Lacs.
The zero revenue from operations in Q4 FY26 suggests a lack of operational activity or sales for the quarter, potentially indicating a significant slowdown or cessation of business functions during that period.
The substantial Net Loss and zero revenue from operations in Q4 FY26 increase financial risk, particularly concerning the company's ability to generate income and cover expenses in the short term.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the reported Net Loss of (Rs. 5,003.73) Lacs for Q4 FY26 and (Rs. 567.08) Lacs for FY26, as well as the negative Other Equity of (Rs. 2,674.47) Lacs.
🔍
Management Signal
The decision to correct and resubmit financial results indicates management's commitment to accurate financial reporting, despite the reported losses.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results — monitor for revival in revenue from operations.
Future board meetings — check for any strategic business initiatives.
Audit reports — verify consistency in financial reporting moving forward.
HIGH RISK
Zero Q4 FY26 revenue and substantial net losses for both the quarter and full year FY26 indicate significant financial challenges.
💡 Investor Takeaway
Welcure Drugs & Pharmaceuticals Ltd. reported a Net Loss of (Rs. 5,003.73) Lacs for Q4 FY26 and (Rs. 567.08) Lacs for the full year FY26. Total income for Q4 FY26 was (Rs. 0) Lacs. This filing supersedes previously submitted results correcting inadvertent errors.
⚖️ Strengths & Concerns
⚠️ Concerns
- Q4 FY26 Total Income was (Rs. 0) Lacs, indicating an absence of revenue from operations for the quarter.
- Net Loss for Q4 FY26 stood at (Rs. 5,003.73) Lacs, with a full-year Net Loss of (Rs. 567.08) Lacs for FY26.
📅 Company Track Record
In a previous filing on June 1, 2026, Welcure Drugs reported a Q4 FY26 Net Profit of Rs. 0.05 Lakh. This current filing, dated November 2, 2026, supersedes that with a corrected Q4 FY26 Net Loss of (Rs. 5,003.73) Lacs, highlighting a significant revision to previously reported financial performance.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What were Welcure Drugs & Pharmaceuticals Ltd.'s financial results for Q4 FY26?
Welcure Drugs & Pharmaceuticals Ltd. reported a Total Income of (Rs. 0) Lacs and a Net Loss of (Rs. 5,003.73) Lacs for the quarter ended March 31, 2026.
What was the full-year Net Profit or Loss for Welcure Drugs & Pharmaceuticals Ltd. in FY26?
For the full year ended March 31, 2026 (FY26), Welcure Drugs & Pharmaceuticals Ltd. reported a Total Income of (Rs. 39,098.87) Lacs and a Net Loss of (Rs. 567.08) Lacs.
Why did Welcure Drugs & Pharmaceuticals Ltd. supersede its previous financial results?
The company superseded its earlier results from May 29, 2026, because certain inadvertent errors were noticed in the figures of the Audited Standalone Financial Results and Statements, which have now been corrected.
What was the Earnings Per Share (EPS) for Welcure Drugs & Pharmaceuticals Ltd. in Q4 FY26 and full year FY26?
The Basic and Diluted Earnings Per Share (EPS) for Q4 FY26 was (Rs. 0.40), and for the full year FY26, it was (Rs. 0.05).
Questions based on this BSE filing only. For information purposes.